Asia Fresh News

Asia Fresh Stories

Archive for February 2013

Frost & Sullivan Selects InterSystems as “2012 Brazil Company of the Year”

leave a comment »

— InterSystems Implemented its Electronic Health System in Brazil for Public and Private Healthcare Networks

MOUNTAIN VIEW, California, Feb. 27, 2013 /PRNewswire/ — Based on its recent analysis of the Healthcare IT market, Frost & Sullivan recognizes InterSystems Corporation( http://www.intersystems.com.br ) with the 2012 Brazil Company of the Year Award. InterSystems has pioneered the implementation of connected electronic health records in the Brazilian market with its InterSystems TrakCare(R)( http://www.intersystems.com.br/produtos/trakcare ) healthcare information system. Headquartered in the United States, InterSystems is succeeding in Brazil by providing a Brazilian edition of TrakCare that meets the needs of local healthcare providers.

InterSystems TrakCare(R) is a unified healthcare information system that is Internet-based and rapidly delivers the benefits of an electronic patient record. Its functionalities were developed based on input from healthcare professionals.

“In response to customer feedback, InterSystems added features to TrakCare such as the powerful ‘closed-loop’ medication management within a unified healthcare information system to improve patient safety and clinician productivity,” said Frost & Sullivan Research Analyst Gabriel Walmory Silveira. “It also offers new clinical summaries, alerts, ‘break-the-glass’ capabilities, and care planning work lists, along with ease-of-use enhancements and a patented technology for unlocking important information often hidden away in clinical notes.”

The company stands out due to its flexibility in dealing with diverse customers. It has provided Electronic Health Record (EHR) solutions for renowned private hospitals and large diagnostic centers; however, one of the most impressive projects was developing a connected EHR system for the Federal District Government of Brasilia hospitals. This endeavor allowed more than 2 million patients in 17 hospitals with 4,400 beds, 61 health centers, polyclinics, diagnostic laboratories and pharmacies to obtain and share electronic patient records.

“The TrakCare solution has not only aided better health management, but also leveraged integrated information through an analytical process to promote preventive health measures among the population,” noted Gabriel Walmory Silveira. “It also offered new clinical summaries, alerts, ‘break-the-glass’ capabilities, and care planning work lists, along with ease-of-use enhancements and a patented technology for unlocking important information often hidden away in clinical notes.”

Before launching a new product or improving its already leading products, InterSystems obtains suggestions from its clients. In addition, InterSystems’ strategy to open branch offices near its main customers demonstrates its partnership-oriented goals. This business approach enables quick and efficient service and support.

Each year, Frost & Sullivan presents this award to the company that demonstrated superior entrepreneurial ability in its industry during the research period. This award signifies the company’s identification of a unique and revolutionary product solution with significant market potential. Additionally, it certifies the company’s marketing strategy as sound and poised for success.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About InterSystems Corporation

InterSystems Corporation is a global leader in software for connected care, with headquarters in Cambridge, Massachusetts, and offices in 25 countries. InterSystems TrakCare(R)( http://www.intersystems.com/trakcare ) is a unified healthcare information system that rapidly delivers the benefits of an electronic patient record. InterSystems HealthShare(R)( http://www.intersystems.com/healthshare ) is a strategic platform for healthcare informatics, enabling information exchange and active analytics across a hospital network, community, region or nation. InterSystems CACHE(R)( http://www.intersystems.com/cache/index.html ) is the world’s most widely used database system in clinical applications. InterSystems Ensemble(R)( http://www.intersystems.com/ensemble/index.html ) is a platform for rapid integration and the development of connectable applications.

InterSystems’ products are used by thousands of hospitals and laboratories worldwide, including all of the top ten hospitals on the Honor Roll of America’s Best Hospitals as rated by U.S. News and World Report. For more information, visit InterSystems.com( http://www.intersystems.com ), www.youtube.com/InterSystemsCorpwww.facebook.com/InterSystems, or @InterSystems on Twitter( http://twitter.com/InterSystems ).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

— The Integrated Value Propositionprovides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

— The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=Contact )

Join Us: Join our community( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=Join )

Subscribe: Newsletter on “the next big thing”( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=PRFooter )

Register: Gain access to visionary innovation( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=Register )

Contact:

Mireya Espinoza

P: +1-210- 247-3870

F: +1-210-348-1003

E: mireya.espinoza@frost.com

SOURCE Frost & Sullivan

– See more at: http://www.newsinfoguide.com/pressrelease/frost-sullivan-selects-intersystems-as-2012-brazil-company-of-the-year_2#sthash.mCwTfPHR.dpuf

Written by asiafreshnews

February 28, 2013 at 1:16 pm

Posted in Uncategorized

Invitation to Destination Moscow Roadshow 2013 – Friday, 1 March

leave a comment »

MOSCOW/PRNewswire/ —
On behalf of the Moscow Government and KPMG, we would like to invite you to a business congress on the topic of Moscow as a business destination. It will take place at the Intercontinental Hotel, Singapore, on 1 March 2013. The main presentations will be between 9am and 12pm. Lunch will be served at 12pm after which there will be opportunities for one-on-one interviews from 1pm.
The congress is part of the Destination Moscow Roadshow 2013 – a series of events and briefings taking place in Singapore, Japan, Germany, the UK and the US that are designed to overcome the information barrier between Moscow and the international business community, building a constructive dialogue with foreign investors and experts.
At the Singapore event, the Moscow Government delegation will be meeting with local authorities and representatives of the local financial and economic community with an interest in business development and establishing business contacts in Moscow.
Keynote speakers will include: Andrey Sharonov, Minister of the Moscow Government and Deputy Mayor of Moscow on Economic Policy; Mikhail Kuzolvel, President and Chairman of the Management Board of JSC Bank of Moscow; and Vera Chistova, Minister of the Moscow Government and Head of the Department of Finance. Discussion will be moderated by:Marc van der Plas, Member of the Executive of KPMG Russia & CIS; and Stefan Dierks, Partner, Global Strategy Group, Moscow.
Key discussion topics include:
Current and future opportunities for cooperation between the business communities in Moscow and Singapore;
Business infrastructure development of the city of Moscow;
Case studies of foreign investors in Moscow;
Current situation and prospects for the Russian economy.
Event details:
Date: Friday 1 March 2013
Time: Presentations: 9am – 12pm (full agenda available on request to
select relevant presentations)
1:1 interviews: 1pm – 4pm (earlier interviews available on request)
Venue: Intercontinental Hotel, Singapore
Source: Moscow City Government

Written by asiafreshnews

February 28, 2013 at 12:37 pm

Posted in Uncategorized

Innovative Partnership Reduces Cost Of Bayer’s Long-Acting Reversible Contraceptive Implant By More Than 50 Percent

leave a comment »

Initiative will expand access to contraceptives for 27 million women in low-income countries
LEVERKUSEN, Germany /PRNewswire/ — An unprecedented group of public and private sector partners has finalized an agreement that will make Jadelle®, an effective, long-acting, reversible contraceptive implant, available to more than 27 million women in the world’s poorest countries at a more than 50 percent price reduction over the next six years.
The Jadelle Access Program – developed and supported through a partnership between Bayer HealthCare AG, the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Governments of Norway, the United Kingdom, the United States and Sweden, and the Children’s Investment Fund Foundation (CIFF) and the United Nations Population Fund (UNFPA) – builds on momentum generated at the July 2012 London Summit on Family Planning, where global leaders pledged to provide an additional 120 million women in developing countries with contraceptive access by 2020. It also supports the recommendations of the UN Commission on Life-Saving Commodities by helping to shape global markets in order to increase the availability of quality, life-saving commodities at an optimal price and volume.
Under the signed agreement, Bayer is reducing the current price of its contraceptive implant, Jadelle®, from US$18 to US$8.50 per unit, effective 1 January 2013, in more than 50 countries globally, including those deemed least likely by the United Nations (UN) Secretary-General to meet the Millennium Development Goals (MDGs) on maternal and child health by 2015. The device, which has been pre-qualified by the World Health Organization (WHO) since September 2009, provides effective contraception for women for up to five years.
“Innovation is the key to our commercial success and at the same time the basis of our social commitment,” said Dr. Jorg Reinhardt, Chief Executive Officer of Bayer HealthCare AG. “We are delighted to make our life-enhancing products accessible to as many people as possible, regardless of their income or where they live, thus making a substantial contribution to improving the health of women and children in developing countries.”
When fully implemented, the Jadelle Access Program will avert more than 28 million unintended pregnancies between 2013 and 2018, and, ultimately, prevent approximately 280,000 infant and 30,000 maternal deaths. In total, the program will save an estimated US$250 million in global health costs.
Today, more than 200 million women and girls in developing countries who do not want to get pregnant lack access to modern contraceptives. Studies have shown that of the 600 million women in developing countries who are using modern methods of family planning only 1 to 2 percent use implants, but that a significantly greater proportion would choose implants if they were consistently available and supported by counseling and clinical services. In many programs where implants are offered today, they are one of the fastest growing methods of choice.
Responding to the urgent call for more effective public-private collaboration at the London Summit on Family Planning, the partners negotiated this price reduction to make this underutilized method more affordable and accessible to women globally, ultimately helping to expand contraceptive options.
“In July 2012, global leaders pledged to provide women around the world with greater access to more contraceptive options, and today, we are one step closer to delivering on this promise,” said Melinda Gates, co-chair of the Bill & Melinda Gates Foundation. “We hope this will be the first of many innovative partnerships that will help give women and girls the power to create better lives for themselves and their families.”
The price of US$8.50 per unit will be available to all entities procuring Jadelle® from Bayer for use in eligible countries. Large agencies, such as UNFPA and the U.S. Agency for International Development (USAID), and non-state providers are currently communicating the price reduction to their country offices and government partners to ensure that the new price is reflected in countries’ contraceptive procurement plans. Procurement processes and logistics cycles for Jadelle will remain unchanged.
Existing in-country voluntary family planning programs run by government agencies and civil society organizations, supported by USAID, UNFPA, the Norwegian Agency for Development Cooperation (NORAD) and the UK Department for International Development (DFID), will help facilitate increased access to this long-acting, reversible contraceptive to provide women and couples with more family planning options.
Bayer HealthCare AG is also working with other partner groups to develop a plan for improving service delivery infrastructure and training health providers to ensure that women have safe, quality access to proper insertion and removal services, as well as counseling.
Additionally, an initiative is underway that would help family planning civil society organizations scale up innovative distribution methods, such as social franchising and mobile clinics. This work is expected to double these organizations’ current capacity for offering implants to broaden method choice within their programs in 2013, with continued expansion in future years.
Source: Bill & Melinda Gates Foundation

Written by asiafreshnews

February 28, 2013 at 12:28 pm

Posted in Uncategorized

Cliantha Research Partners with Acceliant for its Clinical Trials

leave a comment »

BANGALORE, India /PRNewswire/ —
Acceliant, a global technology provider of innovative clinical trial data management solutions, today announced that Cliantha Research, a leading global Contract Research Organization, has chosen Acceliant’s eClinical Suite for their clinical trial data management needs. Acceliant’s integrated e-PRO/EDC system offers a superior solution by allowing all the study data to be readily available, eliminating the integration costs.
Speaking of the partnership, Hitesh Chauhan, Associate Director of Biometrics at Cliantha Research, said, “We evaluated and selected Acceliant eClinical Suite because we found it to be very user-friendly and superior to several other products. Besides being a platform with best-in-class features, Acceliant’s eClinical Suite is architected process and system wise to drive efficiency, lower costs and accelerate clinical trial studies.”
On the occasion, Ven Thangaraj, CTO of Acceliant, said, “The Life Sciences industry is going through dramatic changes and pressures to innovate while keeping costs under control. Acceliant is one of the few integrated EDC-ePRO platforms with innovative workflows and built-in mobility which allows data management from anywhere, anytime.”
Santhosh S. Nagaraj, Acceliant’s India Sales Head, commented, “We are proud to be associated with Cliantha Research and helping them in their clinical studies. Our differentiation as a robust platform that accelerates trials through efficient data management is what helped us win. We look forward to a successful long-term relationship and continued growth in India.”
Acceliant is also pleased to announce its participation at the BioPharma Asia Convention 2013, one of the largest annual biopharmaceutical industry gatherings in Asia. The convention will be held in Singapore from March 18-21. Acceliant will be in Booth #D24 and will showcase its comprehensive eClinical Suite, interact with global experts, and explore more partnership opportunities.
About Cliantha Research
Cliantha Research, a leading life sciences company, is a global full service Contract Research Organization with integrated offerings in Clinical, Bioanalytical, Dermatology, Biometrics, Pathology and Formulation services. The company has its presence in the US, Canada, Mexico, and India. Cliantha Research’s facilities have been audited by the AGES (Austrian regulatory agency), ANSM (French regulatory agency), AEMPS (Spanish regulatory agency), USFDA, MCC (South African regulatory agency), WHO and International companies. The Central Reference lab at Cliantha is accredited by College of American Pathologists (CAP). Cliantha Research has successfully conducted and executed over 5000 studies and has analyzed over 1.5 million samples.
About Acceliant
Acceliant is the medical industry technology division of Trianz, a global technology services and solutions company. A pioneer in the EDC industry, Acceliant has been providing solutions in the clinical trial management space since 1999. The company caters to the needs of the pharmaceutical, biotechnology, medical device, CRO, and non-profit drug research industries. Acceliant has helped facilitate clinical data management in hundreds of trials worldwide encompassing dozens of therapeutic areas for global giants as well as emerging healthcare innovators.
Prashant Bhavaraju
Chief Marketing Officer, Acceliant
info@acceliant.com
+1-408-387-5899
Source: Acceliant

Written by asiafreshnews

February 28, 2013 at 11:53 am

Posted in Uncategorized

RS Components Supports Rapid Prototyping with Availability of New mbed Application Board

leave a comment »

New mbed application board packs in an abundance of connectivity and sensing options for virtually unlimited range of engineering projects


SINGAPORE, Feb. 26, 2013 /PRNewswire/ — RS Components( http://www.rs-components.com/index.html ) (RS), the trading brand of Electrocomponents plc( http://www.electrocomponents.com ) (LSE:ECM), the world’s leading high service distributor of electronics and maintenance products, has announced the availability of a new mbed application board.

(Logo: http://www.prnasia.com/sa/2011/05/04/20110504368830.jpg )

(Photo: http://www.prnasia.com/sa/2013/02/14/20130214150908105994.html )

Based around the mbed developer platform, the new mbed application board includes a host of connectors and external interfaces, eliminating the requirement for add-on boards and thus reducing valuable design time for engineers.

The new application board is credit-card sized (54mm x 86mm) and is specifically designed for use with the mbed NXP LPC1768 microcontroller module. Providing multi-functional capability, the new board enables the maximum number of potential experiments and projects, while retaining board footprint at a minimum.

The mbed application board offers an impressive array of features including a 128 x 32 graphics LCD; a 3-axis accelerometer; temperature sensor; servo-motor headers; PWM controlled LEDs; socket for ZigBee, Wi-Fi and Bluetooth wireless connectivity; Ethernet and USB connectors; and a speaker and I/O audio jacks.

“This new application board is an important addition to the mbed family that allows engineers to experience ARM(R) technology-based programming,” said Mark Cundle, Head of Technical Marketing, RS Components. “Designed specifically for use with the mbed NXP LPC1768, the module saves engineers significant time in project development, and the huge range of connectivity options brings a huge range of ‘Internet-of-Things’ (IoT) applications into play.”

Please click mbed application board( http://www.rs-components.com/mbed ) for more information, and to purchase the from RS stock.

About RS Components

RS Components and Allied Electronics are the trading brands of Electrocomponents plc, the world’s leading high service distributor of electronics and maintenance products. With operations in 32 countries, we offer more than 550,000 products through the internet, catalogues and at trade counters to over one million customers, shipping around 46,000 parcels a day. Our products, sourced from 2,500 leading suppliers, include electronics, automation and control, test and measurement, electrical and mechanical components.

Electrocomponents is listed on the London Stock Exchange and in the last financial year ended 31 March 2012 had revenues of GBP1.27bn.

For more information, please visit the website at http://www.rs-components.com.

Further information is available via these links:

Twitter: @RSElectronics; @alliedelec; @designsparkRS

RS Components on Linkedin

http://www.linkedin.com/company/rs-components

Relevant Links:

Electrocomponents plc
http://www.electrocomponents.com

RS Components
http://www.rs-components.com

DesignSpark
http://www.designspark.com

RS Components
Tan Soo Chun
Public Relations Manager – Asia Pacific
Email: soochun.tan@rs-components.com
Tel: +65-6391-5745

The Hoffman Agency
Rasheed Abu Bakar
Senior Account Executive
Email: rscsg@hoffman.com
Tel: +65-6361-0250

SOURCE﹛RS Components

Written by asiafreshnews

February 28, 2013 at 11:25 am

Posted in Uncategorized

/C O R R E C T I O N — dotMobi/

leave a comment »

BARCELONA, Spain /PRNewswire/ — In the news release,dotMobi Brings Detailed Device Intelligence to the Carrier Environment, issued 26-Feb.-2013 by dotMobi over PR Newswire, we are advised by the company that the second boilerplate was inadvertently included in the release. The complete, corrected release follows:
dotMobi Brings Detailed Device Intelligence to the Carrier Environment
– dotMobi’s device data platform DeviceAtlas maps IMEI data to device capabilities
Mobile Web technology expert dotMobi today announced the addition of International Mobile Equipment Identifier (IMEI) data to its DeviceAtlas mobile device data platform. This enhancement extends DeviceAtlas’ lead as the most authoritative source of device data available.
The addition of IMEI data allows DeviceAtlas to connect the carrier environment — where the Type Allocation Code (TAC) component of IMEI data is the standard way to identify handsets — with detailed device information on the more than 10,000 devices already contained in the DeviceAtlas device database.
For all GSM devices produced, device manufacturers are required to have a TAC, assigned by the GSMA, to identify the make and model; TACs are embedded in the IMEI number. Combining this code with DeviceAtlas data provides 140 detailed characteristics of the device (for example, operating system, browser, multimedia capabilities, screen size, etc.) that enable expanded service to mobile devices.
The many players at the mobile network level, who already receive IMEI information via SMSC, MMSC or WAP gateways, will benefit from combined DeviceAtlas and IMEI data by having detailed data about each handset on the network. This information can be used in multiple ways, including delivery of content and ads targeted to specific devices, over-the-air (OTA) device management, policy management for roaming devices and identification of counterfeit devices.
Eileen O’Sullivan, dotMobi COO, said, “Bringing together the high-quality data available through DeviceAtlas with IMEI data opens a wide range of potential applications for operators and their partners to address all handsets on their networks, accurately and quickly. Since dotMobi was created by leading mobile operators, device manufacturers and Internet content providers, we understand what carriers require to meet the needs of their growing customer bases.”
About dotMobi
Headquartered in Dublin, dotMobi — a wholly owned subsidiary of Afilias Limited — is a worldwide leader in enabling the development & discovery of quality mobile content through innovative services, in turn helping businesses and individuals reach the world’s billions of mobile phone users. dotMobi spurs mobile industry innovation by giving content providers the tools they need to ensure the Web will work on mobile devices with speed, accuracy and relevant content. Visit dotMobi for more information on .MOBI domains and all dotMobi services, including DeviceAtlas and the goMobi mobile website publishing solution.
For more information, please contact:
Martin Clancy
dotMobi
+353-1-854-1134
mclancy@dotmobi.mobi
Vance Hedderel
dotMobi / Afilias
+1-703-485-5563
vhedderel@afilias.info
Source: dotMobi

Written by asiafreshnews

February 27, 2013 at 5:08 pm

Posted in Uncategorized

Amobee Joins Forces With Four Large Mobile Operators to Bring Big Data to Mobile Advertising

leave a comment »

– Amobee providing big data mobile ad serving platform for Globe, Optus, SingTel and Telkomsel

SINGAPORE and BARCELONA, Spain, Feb. 26, 2013 /PRNewswire/ — Amobee, the company defining mobile advertising, today announces their exclusive partnership with four leading mobile operators: Globe, Optus, SingTel and Telkomsel. Amobee’s publisher-side mobile advertising platform, PULSE for Publishers, is now fully operational in the region and gives these large operators the ability to lead the mobile advertising ecosystem in Asia with data-rich, privacy compliant inventory, which is the holy grail of mobile advertising.

(Logo: http://photos.prnewswire.com/prnh/20120125/SF41724LOGO-a )

With Amobee’s leading-edge mobile advertising technology, Globe, Optus, SingTel and Telkomsel can now provide global brands with the most relevant, high quality mobile advertising inventory to reach the fast-growing Asian market. The Amobee PULSE for Publishers platform gives each of these operators the ability to enhance mobile inventory with targetable user data, therefore enabling brands to achieve better results by reaching the right consumers, at the right time, in the right place, with the right offer.

Allen Lew, CEO of Group Digital L!fe, SingTel, said, “Consumers are increasingly choosing mobile devices for the consumption of content and to conduct research for their purchases. Many of them are also warming up to targeted ads which reflect their interests, connections or locations. This makes the mobile space increasingly relevant for brands and advertisers.”

He added, “By working with Amobee, the SingTel Group is extracting value from our unique assets – the scale of our regional customer base and our deep customer insights – to offer mobile advertisers the most mileage out of their spend. With the rich data we have, they can benefit from a more targeted and segmented customer reach. At the same time, our customers will benefit from personalised, highly relevant and non-intrusive mobile ads which are delivered in a legally compliant manner.”

“The Philippines is one of the fastest growing, mobile-centric markets in the world, where nearly every Filipino owns a mobile device rather than a computer. Therefore, it has become crucial that advertisers and brands stay on top of consumers’ minds with relevant mobile ads,” said Ernest Cu, CEO of Globe. “Our partnership with Amobee will be essential in providing the most intuitive mobile offering to brands looking to leverage our unparalleled reach in this market.”

“Amobee is excited to partner with Globe, Optus, SingTel and Telkomsel to make Asia the global leader in mobile advertising,” said Trevor Healy, CEO of Amobee. “More importantly, we are using operators’ big data to fuel better targeting.”

About Amobee
Amobee, the company defining mobile advertising, offers comprehensive, end-to-end mobile advertising solutions and services for advertisers, publishers and operators worldwide. Headquartered in Redwood City, California, with offices in Europe, Asia, Australia, Latin America and throughout the United States, Amobee enables its large customers to run targeted, leading edge mobile ad campaigns on a global scale with unparalleled ROI. Amobee is a division of SingTel’s Group Digital L!fe, which is focused on creating new digital growth engines to delight customers and disrupt adjacent industries. Amobee was declared the winner of the “Mobile Marketing & Advertising Agency of the Year” award at the 17th Annual Global Mobile Awards, held at the GSMA Mobile World Congress in Barcelona. Amobee was selected for its sustained leadership, creativity, innovation and success in mobile advertising, successfully spearheading growth, adoption and evolution of this fast-growing industry.

Source: Amobee

Written by asiafreshnews

February 27, 2013 at 5:01 pm

Posted in Uncategorized

White Top Containerboard usage to experience continued growth in Europe

leave a comment »

BOSTON, Feb. 26, 2013 /PRNewswire/ — Demand growth for white top liners has increased significantly higher than the overall growth in corrugated packaging during the past year. According to a study published today by RISI, the leading information provider for the global forest products industry, white top liner segments will likely post better profit margins over their brown counterparts as demand for white top liner in Europe continues to grow. 2012 Outlook for European White Top Containerboard Markets with 2013 Update examines and forecasts market developments until 2016.

(Logo: http://photos.prnewswire.com/prnh/20080521/NEW122LOGO)

“Over the last decade, the European containerboard market has already grown by close to 5 million tonnes. Although white top liners only make up a 12% share of total European containerboard demand, demand for white top liners is being driven upward by printing quality requirements on the part of end-users and brand owners for retail-ready packaging,” said Orifjon Abidov, Senior Economist for European Paper Packaging at RISI.

2012 Outlook for European White Top Containerboard Markets with 2013 Update provides a historical analysis of the white top containerboard market from 2002 – 2012 and covers supply and demand trends by country, trade, production costs, pricing, and profitability until 2016.

Outlook for European White Top Containerboard Markets Includes:

  • Recent trends in European containerboard markets
  • European White Top Containerboard Producers and their market shares
  • Demand growth rate changes for each containerboard grade since 2002
  • Capacity growth rate movements since 2002
  • Anticipated European White Top Testliner and White Top Kraftliner market developments through 2016
  • Price trends for White Top Testliner and White Top Kraftliner since 2000
  • Production costs and price changes over the next five years
  • Profitability developments for White Top Containerboard since 2000
  • Profitability expectations over the next five years

About RISI (www.risi.com) Owned by UBM plc, which is listed on the London Stock Exchange, RISI is the leading information provider for the global forest products industry. The company works with clients in the pulp and paper, wood products, timber, biomass, tissue, nonwovens, printing and publishing industries to help them make better decisions.

Headquartered in Boston, MA, RISI operates additional offices throughout North and South America, Europe and Asia.

About UBM plc ( www.ubm.com )
UBM plc is a leading global company. We inform markets and bring the world’s buyers and sellers together at events, online, in print and provide them with the information they need to do business successfully. We focus on serving professional commercial communities, from doctors to game developers, from journalists to jewelry traders, from farmers to pharmacists around the world. Our 6,000 staff in more than 30 countries are organized into specialist teams that serve these communities, helping them to do business and their markets to work effectively and efficiently.

For Press Enquiries, please contact:
Gianna DeMonte
Communications Associate
O: +1.781.734.8965
E: gdemonte@risi.com

Written by asiafreshnews

February 27, 2013 at 4:53 pm

Posted in Uncategorized

UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals

leave a comment »

NEW YORK, Feb. 26, 2013 /PRNewswire/ — UBM DeusM and UBM Live today launched PharmaEvolution.com (www.pharmaevolution.com), a new online community that will address the needs of professionals in pharmaceutical research and development, manufacturing, supply chain management, and quality.

PharmaEvolution.com will establish a global, peer-to-peer network to help professionals grapple with the sweeping changes affecting the pharmaceutical industry today. It will leverage the strength of UBM Live’s CPhI global exhibition and conferences brand and DeusM’s expertise in developing vital, engaged online communities.  It will also draw from the example of UBM Medica’s successful online oncology nurse community, TheONC.org.

“For pharmaceutical professionals today there’s an enormous pressure to innovate and manufacture more efficiently, with fewer resources, all while improving product safety and quality,” says PharmaEvolution.com editor, Agnes Shanley. “There’s a real need for better risk management and more scientific approaches to quality assurance and control.”

On PharmaEvolution, leaders in the industry’s evolution to more innovative R&D and manufacturing share best-practices, self-assessment tools, technical articles, webcasts, chat, and nontraditional formats designed to help professionals improve results.

Rather than aggregated content written by journalists, PharmaEvolution.com will feature original content, written mainly by industry professionals.  It will create a safe and secure online environment where peers can share best nonproprietary practices, troubleshoot problems, and openly discuss challenges and issues without intrusive marketing messages, unethical use of personal information, or unfocused discussion.

Content on the site focuses on those areas most critical to the industry and the patients and physicians it serves:  R&D, manufacturing and quality, formulation, APIs and excipients, drug delivery, packaging and anti-counterfeiting, regulatory compliance, contract services, and supply chain management.

Pharma Evolution is published by UBM Live, UBM DeusM, and founding sponsor Capsugel, along with Aptalis, Harlan, and B-Braun. Capsugel is an established pharma industry leader, specializing in dosage form development for more than 100 years.

Go here to visit Pharma Evolution: http://www.pharmaevolution.com.

Contact:
Amy Averbook
Sr. Marketing Director
UBM DeusM
(917) 743-2693
averbook@deusm.com

About UBM Live
UBM Live connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their markets. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.

About UBM DeusM
UBM DeusM (www.deusm.com) is an integrated marketing services company owned by UBM plc, targeting the fastest growing segment of the online publishing industry: business social media. The company is led by Managing Director Stephen Saunders, Min’s Marketer of the Year 2010. He and the other UBM DeusM principals have built and delivered more than 45 successful sites and online communities over the last two years. UBM DeusM’s service is based on a unique platform, called Community in a Box (CiaB), which employs a structured system of proven B2B Web publishing best-practices, combined with a breakthrough integrated multimedia publishing platform (“n-Server”) to enable marketers to quickly and profitably set up specialized communities for their target customers.

Written by asiafreshnews

February 27, 2013 at 4:43 pm

Posted in Uncategorized

Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal

leave a comment »

 

WASHINGTON and CRANBURY, New Jersey, Feb. 26, 2013 /PRNewswire/ — Viropro, Inc. (OTC: VPRO) and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement.  Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China).  Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro’s Penang, Malaysia Alpha Biologics biomanufacturing subsidiary.  The alliance will seek regional partners to drive commercialization.

The six biosimilars are generic versions of Humira®, Rituxan®, Avastin®, Herceptin®, Erbitux® and one other non-disclosed biotherapeutic.  These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion with more than $6 billion in the emerging countries covered by the agreement.  The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.

“The Oncobiologics biosimilars program is a perfect complement to Viropro’s biomanufacturing expertise.  Their scientific team is comprised of recognized industry veterans and we are impressed by the high quality of the science they are achieving,” said Viropro President & CEO Cynthia Ekberg Tsai.  “This partnership brings together high-quality molecules developed to FDA and EU regulatory standards integrated with world class biomanufacturing, the net result being high quality products with low cost of goods.  Together we are well positioned to provide emerging countries access to affordable, high-quality biopharmaceutical products for critical indications.”

Oncobiologics Founder and CEO, Pankaj Mohan, Ph.D., added, “We are thrilled to have Viropro as an anchor partner. Together we form a fully integrated biopharmaceutical alliance to serve the emerging markets.  The combination of a state-of-the-art biologics manufacturing facility and support from the Malaysian Government makes Viropro an ideal partner. This unique partnership allows us to bring together technical expertise and quality oversight from the U.S. with a high capability, low cost biologics operation in Malaysia.”

Dato’ Dr. Mohd Nazlee Kamal, CEO of Malaysian BiotechCorp, commented, “Malaysia’s strategy to become a biotech hub for Asia is rapidly gaining traction, and this Viropro/ Oncobiologics partnership is a significant step in moving this effort forward. BiotechCorp is proud to be part of this collaboration and we look forward to many great developments. This project will attract interest in the biosimilars manufacturing field and will certainly build the confidence of global biotech companies in Malaysian companies as we strive to develop the biomedical sector in the country.”  Malaysian BiotechCorp is an agency under the Ministry of Science, Technology and Innovation (MOSTI) responsible for executing the objectives of the National Biotechnology Policy (NBP).

Proximare, a strategic advisory firm focused on the life sciences and healthcare industries, acted as advisor for the deal.   Financial terms were not disclosed.

About Oncobiologics, Inc.

Oncobiologics is a privately-held biopharmaceutical company developing a pipeline of biosimilars and next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 30,000 sq.ft. R&D facility in Cranbury, NJ. For more information, please visit www.oncobiologics.com

About Viropro Inc.

Viropro specializes in the development and manufacturing of biopharmaceutical drugs.  Alpha Biologics is the manufacturing arm of Viropro, located on the Penang Science Park located in North Malaysia.  Alpha operates a 50,000 sq. ft. state of the art facility designed by Boccard (France). The Alpha facility has undergone a regulatory agency design review and uses a combination of stainless steel and single-use equipment to maximize operational performance for our manufacturing partners. For more detailed information about the company, visit www.viropro.net

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements in this release may be identified through the use of such words as “expects”, “anticipates”, “estimates”, “believes”, or statements indicating certain actions “may”, “could”, or “might” occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company’s ability to market its products and services in a competitive environment as well as other factors.

Written by asiafreshnews

February 27, 2013 at 4:31 pm

Posted in Uncategorized